Senores Pharmaceuticals Limited (SPL), through its US subsidiary SPI, has acquired the USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets 2.5mg, 5mg, 10mg, and 20mg from Wockhardt Limited.
Enalapril is used to treat hypertension, heart failure, and asymptomatic left ventricular dysfunction.
The market size for Enalapril Tablets in the USA is approximately USD 28.60 million (MAT December 2024) as per IQVIA and USD 109.24 million (MAT March 2025) as per Symphony.
The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL, aligning with the IPO objectives.